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Imaging Improves Diagnosis of Dementia   
with Lewy Bodies 
 
 
 
Dementia with Lewy bodies (DLB) is the second most common cause of degenerative de-
mentia after Alzheimer’s disease (AD), and is clinically characterized by the progressive 
cognitive decline with fluctuations in cognition and alertness, recurrent visual hallucina-
tions and Parkinsonism. Once these characteristic symptoms of DLB emerge, discriminat-
ing it from AD is relatively easy. However, in the early disease stages, the clinical symptoms 
of various types of dementias largely overlap and it is difficult to distinguish DLB from 
other neurodegenerative dementias based on clinical manifestations alone. To increase the 
accuracy of antemortem diagnosis of DLB, the latest diagnostic criteria incorporate findings 
from 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, or from neuroimag-
ing such as computed tomography (CT), magnetic resonance imaging (MRI), single pho-
ton emission computed tomography (SPECT), and positron emission tomography (PET). 
In the present guidelines, decreased dopamine transporter uptake revealed by SPECT or PET 
receives the greatest importance among various neuroimaging findings and is listed as one 
of the suggestive features. Supportive features that commonly present but are not proven to 
have diagnostic specificity include relatively-preserved medial-temporal-lobe structures, 
occipital hypoperfusion, and abnormal MIBG myocardial scintigraphy. In this paper, we 
review the major findings on various neuroimaging modalities and discuss the clinical use-
fulness of them for the diagnosis of DLB. Although there is not enough evidence to reach the 
conclusion, considering the accessibility in clinical practice, in our personal views, we re-
commend the use of brain-perfusion SPECT and MIBG myocardial scintigraphy to improve 
the diagnosis of DLB.   Psychiatry  Invest  2009;6:233-240
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Historical Background of Dementia with Lewy Bodies 
 
The concept of dementia with Lewy bodies (DLB) was first proposed in a case 
report by a Japanese psychiatrist, Dr. Kenji Kosaka, in 1976.
1 Two years later, based 
on their neuropathological findings from three autopsied cases, Kosaka
2 reported the 
characteristic distribution of Lewy bodies in cerebral cortices in the subjects with
the later so-called “diffuse Lewy body disease (DLBD)”. After the accumulation of
similar cases, the term “Lewy body disease” was introduced and used to represent a
spectrum of diseases involving an array of cognitive dysfunctions and motor sym-
ptoms.
3 The spectrum could be divided into three types of disease according to the
distributional pattern of Lewy bodies: the diffuse type, the transitional type and the 
brain stem and diencephalon type.
4 The brain stem type is equivalent to Parkinson 
disease (PD), and the diffuse type is later designated as DLBD. Furthermore, Kosa-
ka’s group reviewed all reported DLBD cases in Japan and classified them into two
subtypes; the common form contained various degrees of Alzheimer’s pathology
while the pure form never had such neuropathological findings. Then, in 1984, the   
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term DLBD was proposed as a broader clinical entity 
which included various types of medical conditions with 
Lewy bodies.
4 In short, Lewy body disease was referred 
to by various names such as Lewy Body disease, Lewy 
Body dementia, diffuse Lewy Body disease and DLB. The 
mixture of these words confused the clinicians till they 
reached a certain degree of consensus. Based on the ac-
cumulating cases, the definition of the term “DLB” was 
proposed and approved at the first international work-
shop in 1995.
5 The publication of clinical guidelines for 
DLB highlighted a previously under-diagnosed condition 
and illuminated this clinical entity.
6 However, several cli-
nical studies revealed that the initial diagnostic criteria 
had insufficient sensitivity for reliable DLB recognition.
7 
To achieve acceptably-high sensitivity and specificity, the 
guidelines were revised and released anew in 2005.
8 The 
revised version of guidelines has been well accepted and 
used worldwide both for clinical and research purposes. 
 
Neuroimaging Studies 
in Dementia with Lewy Bodies 
 
Currently, DLB is reported to be the second most com-
mon cause of degenerative dementia after Alzheimer’s 
disease (AD).
7-11 Since DLB causes characteristic impair-
ments and disabilities such as neuroleptic hypersensiti-
vity which may increase mortality, its prompt and cor-
rect diagnosis is very important. However, because the 
clinical symptoms of DLB and AD overlap in the early 
disease stages, it is difficult to distinguish DLB from AD 
based on clinical manifestations alone.   
To increase the accuracy of antemortem diagnosis of 
DLB, the latest diagnostic criteria (Table 1) incorporate 
findings from 123I-metaiodobenzylguanidine (MIBG) 
myocardial scintigraphy, or from neuroimaging such as 
computed tomography (CT), magnetic resonance imag-
ing (MRI), single photon emission computed tomography 
(SPECT), and positron emission tomography (PET).
8 This 
imaging provides highly objective and precise data that 
contributes to the clinical diagnosis of DLB. For example, 
among three suggestive features in the diagnostic criteria 
of DLB: rapid eye movement (REM) sleep behavior dis-
order, severe neuroleptic sensitivity and low dopamine 
transporter uptake, the measurement of dopamine trans-
porter activity in striatum by SPECT or PET enables the 
most objective and highly accurate assessment of char-
acteristic abnormalities in DLB and could be a helpful 
diagnostic aid in discriminating DLB and AD. Supportive 
TABLE 1. The latest guidelines for the diagnosis of DLB
1. Central feature (essential for a diagnosis of possible or probable DLB) 
Dementia, defined as progressive cognitive decline of sufficient magnitude to interfere with normal social or occupational function. 
Prominent or persistent memory impairment may not necessarily occur in the early stages but is usually evident with progression. 
Deficits on tests of attention, executive function, and visuo-spatial ability may be especially prominent. 
2. Core features (two core features are sufficient for a diagnosis of probable DLB, one for possible DLB) 
Fluctuating cognition with pronounced variations in attention and alertness. 
Recurrent visual hallucinations that are typically well formed and detailed. 
Spontaneous features of Parkinsonism. 
3. Suggestive features (If one or more of these is present in the presence of one or more core features, a diagnosis of probable DLB can 
be made. In the absence of any core features, one or more suggestive features is sufficient for possible DLB. Probable DLB should not 
be diagnosed on the basis of suggestive features alone.) 
REM sleep behavior disorder 
Severe neuroleptic sensitivity 
Low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET imaging 
4. Supportive features (commonly present but not proven to have diagnostic specificity) 
Repeated falls and syncope 
Transient, unexplained loss of consciousness 
Severe autonomic dysfunction, e.g., orthostatic hypotension, urinary incontinence 
Hallucinations in other modalities 
Systematized delusions 
Depression 
Relative preservation of medial temporal lobe structures on CT/MRI scan 
Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity 
Abnormal (low uptake) MIBG myocardial scintigraphy 
Prominent slow wave activity on EEG with temporal lobe transient sharp waves 
The latest guidelines for the diagnosis of DLB are shown in this table. Items 5 (a diagnosis of DLB is less likely) and 6 (temporal sequence of 
symptoms) are omitted.8 The features related to imaging are highlighted in bold type. DLB: dementia with Lewy bodies, REM: rapid eye 
movement, SPECT: single photon emission computed tomography, PET: positron emission tomography, CT: computed tomography, MRI:
magnetic resonance imaging, MIBG: 123I-metaiodobenzylguanidine, EEG: electroencephalogram    
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features include relatively preserved medial temporal lobe 
structures, occipital hypoperfusion/metabolism, and de-
creased MIBG uptake on myocardial scintigraphy. The 
results of CT, MRI, PET and brain-perfusion SPECT 
could be evaluated by statistical analyzing programs ob-
jectively. 
In this paper, we give a brief overview of studies in 
DLB using various imaging modalities. 
 
Morphological neuroimaging studies 
Morphological neuroimaging, such as brain CT and 
MRI, is often performed for the clinical diagnosis of va-
rious types of dementia.
12 The main aims of this imag-
ing are the detection of cerebrovascular diseases, space-
occupying legions such as hematoma and brain tumor, 
and the evaluation of the degree of cerebral atrophy.
13-15 
In regard to the diagnosis of DLB, there is no confirmed 
characteristics with a significant diagnostic value from 
morphological neuroimaging.
12 In the consensus guide-
lines,
8 relatively-preserved medial-temporal-lobe struc-
tures on CT/MRI are alone listed as one of the supportive 
features in DLB. These are commonly present but are not 
proven to have diagnostic specificity.   
 
Region-of-Interest Based Analyses 
Previous morphological neuroimaging studies used re-
gion-of-interest (ROI) based analyses to assess the degree 
of cerebral atrophy. In this method, one needed to place 
the ROIs manually, and only selected regions could be 
investigated.  
Morphological neuroimaging studies using visual in-
spection or ROI techniques demonstrated that the extent 
of medial temporal lobe atrophy was severer in AD com-
pared to DLB.
16-20 Hashimoto et al.
17 reported that hip-
pocampal volume in DLB was significantly larger than 
that in AD, but significantly smaller than in the normal 
control. In their study, no significant differences were 
found in the amygdala and whole-brain volume between 
DLB and AD, though the amygdala and whole brain were 
smaller in DLB compared to the control. These findings 
were consistent with the results of the study by Barber 
et al.
16 that demonstrated that the subjects with DLB had 
significantly larger temporal-lobe, hippocampal, and am-
ygdala volumes than those with AD. Their results also 
reported that significant ventricular dilation was observ-
ed in the subjects with AD, vascular dementia (VaD) and 
DLB, and only the subjects with DLB had a relatively 
preserved volume of the cerebrum. The medial temporal 
lobe atrophy in DLB has been reported to be related to 
age and cognitive impairment.
19,20 Therefore, clinicians 
need to take the patients’ history carefully and examine 
clinical symptoms thoroughly before interpreting the re-
sults of neuroimaging. 
Besides the temporal lobe, other cerebral structures have 
been studied morphologically. Almeida et al.
21 reported 
that there were no significant differences in caudate nu-
cleus volume in DLB, AD, PD, PD with dementia (PDD) 
and controls. However, Cousins’s group demonstrated that 
the volume of putamen was smaller in DLB compared 
to AD and normal controls.
22 Regarding the atrophy of 
substantia innominata, Hanyu and his colleagues
23 showed 
significant reduction of the volume only in DLB, while 
the volume was preserved in AD, VaD and the control. 
 
Voxel-Based Morphometry 
Voxel-based morphometry (VBM) is one of the neuro-
imaging analysis techniques that investigate morpholo-
gical differences by using statistical parametric mapping 
(SPM).
24,25 VBM enables objective and quantitative an-
alysis of brain structure.   
Compared to the normal control, decreased volume of 
the temporal and frontal lobes and insular cortex was 
found in DLB by Burton’s group.
26 The MRI study done 
by Whitwell et al.
27 revealed decreased volume of the 
dorsal midbrain, substantia innominata and hypothalamus. 
Brenneis et al.
28 demonstrated the atrophy of lateral pre-
frontal cortex and left premotor cortex in DLB.   
In regard to the comparison between DLB and AD, AD 
patients showed decreased volume in the medial tempo-
ral lobe, hippocampus, amygdala and thalamus in Bur-
ton’s study,
26 in the hippocampus and temporo-parietal 
cortex in Whitwell’s study,
27 and in the temporal and fron-
tal lobe in Beyer’s study.
29 
Taken together, we can conclude that the relatively-
preserved volume of the medial temporal lobe could be 
a support for the diagnosis of DLB, especially for the dis-
crimination of DLB from AD. 
 
Diffusion Tensor Magnetic Resonance Imaging 
Diffusion tensor imaging (DTI) is an advanced neu-
roimaging technique that performs a more sensitive in-
vestigation of tissue microstructure compared to con-
ventional imaging methods, and enables the extraction 
of white matter connections of the brain using tracto-
graphy.
30-33 A number of studies have reported the use-
fulness of DTI for investigating the pathophysiological 
mechanisms of DLB.
34,35 Firbank et al.
36,37 demonstrated 
a decreased fractional anisotropy in the parietal lobe in 
DLB and an increased apparent diffusion coefficient in 
the left temporal lobe in AD, suggesting the region-spe-
cific disruption of the connectivity in respective demen-
tias. Bozzali et al.
38 revealed abnormalities in brain re-
gions with long connecting tracts, which suggested the 
involvement of association cortices in neurodegenerative  
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process in DLB. This group also demonstrated that no 
significant abnormality was found in the occipital region 
of AD subjects and normal controls, and suggested that 
DTI could be a support tool for the diagnosis of DLB.
39 
Ota and his colleagues
40 applied DTI to examine the me-
chanisms of visual hallucination in DLB and indicated 
the possible involvement of inferior longitudinal fascicu-
lus which played an important role in visuo-spatial cog-
nition. 
 
Functional neuroimaging studies 
The initial consensus guidelines for the clinical diag-
nosis of DLB
5 proved to be insufficiently sensitive for 
reliable DLB recognition.
7 To increase the accuracy of 
the clinical diagnosis of DLB, the latest diagnostic cri-
teria incorporate findings from SPECT or PET, and include 
reduced occipital perfusion as a supportive feature.
8 
 
Single Photon Emission Computed Tomography 
Brain-perfusion SPECT is often performed for the diag-
nosis of dementia, along with CT and/or MRI. Character-
istic hypoperfusion in the hippocampus, posterior cingu-
late gyrus and temporoparietal cortex is very useful for 
the early detection of AD.
41-44 The most important find-
ing on brain-perfusion SPECT in DLB is occipital hypo-
perfusion. This hypoperfusion is listed as a supportive 
feature in the consensus guidelines.
8 
To increase the accuracy of the clinical evaluation and 
to achieve the highest possible agreement between dif-
ferent readers, algorithms for analyzing SPECT images 
have been developed and used in the clinical setting. Two 
widely used methods are SPM
45,46 and three-dimension-
al stereotactic surface projection (3D-SSP).
47-51 In both 
algorithms, SPECT images are anatomically standardized 
and statistically analyzed. Both SPM and 3D-SSP enable 
us to detect cerebral regions with lowered blood perfus-
ion with statistical significance. Since SPM uses the t-
test for statistical analysis, when the degrees of freedom 
of the sample are small, the sensitivity can be lowered 
while specificity remains high. 3D-SSP has high sensi-
tivity and specificity. However, as the images are pro-
jected to the surface of the schematic brain, it is difficult 
to determine the exact region of abnormal blood flow. 
To make better use of the advantages discussed above, 
Matsuda et al. developed a new qualitative analysis me-
thod named eZIS.
52-55 This method is accompanied by a 
database prepared from age-matched normal controls, 
and compares the results of individual subjects with the 
database for statistical analysis. The extent of the decrease 
of cerebral blood flow is expressed as a set of Z-values. 
Each value equals the division of the difference between 
the mean of the normal controls and the result from the 
subject by the standard deviation of the normal controls. 
The Z-value results are shown as a projection chart on a 
schematic brain. Furthermore, Takeuchi et al. developed 
a fully-automated rCBF quantification method, 3DSRT, 
which allowed objective assessment of rCBF by setting 
the ROIs identically on anatomically-standardized SPE-
CT images.
56-59 3DSRT includes anatomical standardi-
zation of images employing SPM which is used only for 
that purpose, rCBF quantification using a three-dimen-
sional stereotactic ROI template, calculation of CBF and 
display of the results.   
The initial SPECT studies using 99mTc-hexamethyl 
propyleneamine oxime (HMPAO) as a tracer suggested 
limited value of such studies for the differential diagno-
sis of DLB from AD.
60-62 However, the following rese-
arch demonstrated that occipital hypoperfusion revealed 
by brain-perfusion SPECT had high enough sensitivity 
and specificity to distinguish DLB from other dementias. 
Ishii et al.
63 performed HMPAO-SPECT in DLB, AD 
and healthy control, and analyzed their results by using 
SPM. The analysis results revealed decreased cerebral 
blood flow in the occipital lobes. Lobotesis et al.
64 re-
ported that blood perfusion in AD and DLB differed 
only in occipital areas and distinguished DLB from AD 
and control subjects with a 65% sensitivity and 87% spe-
cificity which were equal to Varma’s study.
65 Colloby and 
his colleagues
66 investigated the results of the HMPAO-
SPECT performed in 48 AD, 23 DLB and 20 control sub-
jects, and indicated hypoperfusion in both parietal and 
occipital regions of the brain in DLB compared to the 
AD group. 
Pasquier et al.
67 used 99mTc-ethylcysteinate dimer 
(ECD) as a tracer for their brain-perfusion-SPECT study 
and obtained a similar sensitivity of 65% for the diagno-
sis of DLB. Our group performed ECD-SPECT in 25 
DLB subjects and analyzed the results by using eZIS.
68 
The sensitivity calculated in our study was 68% and this 
value was equivalent to the previous studies. On the whole, 
the sensitivity of brain-perfusion SPECT has been reported 
to be around 60-70%.   
We performed quantitative analysis of brain-perfusion 
SPECT in DLB and demonstrated the clinical usefulness 
of an automated cerebral blood flow quantification pro-
gram, 3DSRT, for the diagnosis of DLB.
69 3DSRT en-
abled us to estimate the blood perfusion in the region of 
interest. In the comparison of the usefulness of different 
SPECT analyzing programs, the 3DSRT analysis of brain-
perfusion SPECT in DLB showed higher sensitivity (76%) 
compared to that of eZIS (68%).
68 
 
Positron Emission Tomography 
Cerebral metabolism is often measured for the clini- 
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cal diagnosis of dementias by using fluorodeoxyglucose 
(FDG) and PET.
70 Characteristic regional hypometabo-
lism could be useful to differentiate DLB from other de-
mentias.  
Albin and his colleagues
71 were the first to report hy-
pometabolism in the occipital association cortex and pri-
mary visual cortex in DLB. In the following year, Im-
amura and his colleagues
72 verified Albin’s findings by 
investigating a bigger sample. Ishii et al.
73 performed 
FDG-PET and investigated the regional cerebral meta-
bolic rate of glucose in three groups: DLB, AD and con-
trols. Their results demonstrated that the decreased me-
tabolic rate in the occipital region could distinguish DLB 
from AD with a sensitivity and specificity of 92% each. 
His group suggested that occipital hypometabolism might 
be associated with visual hallucinations in DLB.
74 The 
PET study conducted by Higuchi’s group indicated that 
the glucose metabolism was significantly reduced in the 
visual association cortex of DLB subjects compared to 
the AD group.
75 Minoshima et al.
76 examined cerebral glu-
cose metabolism in the subjects with autopsy-confirmed 
DLB (n=11) and AD (n=10) along with 53 probable AD 
subjects including 13 cases who later received a clinical 
diagnosis of DLB. In their study, hypometabolism in the 
primary visual cortex distinguished DLB from AD with 
90% sensitivity and 80% specificity.   
 
Dopamine Transporter Imaging   
In the latest criteria for the clinical diagnosis of DLB, 
decreased dopamine transporter (DAT) uptake in the ba-
sal ganglia is listed as one of the suggestive features.
8 If 
one or more suggestive features is present in combination 
with one or more core features, a diagnosis of probable 
DLB can be made, whereas in the absence of any core 
features, one or more suggestive features is defined as 
possible DLB. Thus, DAT imaging receives the highest 
priority among various neuroimagings. To investigate 
the striatal DAT function in DLB, two kinds of ligands 
for SPECT imaging are used: [123I]-2beta-carbometoxy-
3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FP- 
CIT) and [123I]-2beta-carbomethoxy-3beta-(4-iodoph-
enyl)tropane (beta-CIT). Donnemiller et al.
62 performed 
beta-CIT SPECT on 7 probable DLB, 6 probable AD and 
3 normal controls, and indicated that low DAT function 
was useful to discriminate DLB from AD and normal 
controls. His group also performed SPECT imaging by 
using beta-CIT on 20 DLB patients, 24 subjects with PD 
and 10 normal controls, and demonstrated that DAT im-
aging might be useful to distinguish DLB and PD.
77 As 
to FP-CIT, O’Brien’s group used this ligand and per-
formed DAT imaging on probable/possible DLB, PD, 
PDD, AD and normal controls.
78 Their results demonst-
rated that the sensitivity, specificity and positive predic-
tive value for the differentiation of DLB from AD were 
78%, 94% and 90%, respectively, though it was difficult 
to separate DLB from PD with and without dementia. 
McKeith et al. lead a multicenter study about FP-CIT 
SPECT on DLB and assessed 326 patients including pro-
bable (n=94) or possible (n=57) DLB or 147 non-DLB 
dementia.
79 They calculated a mean sensitivity of 77.7% 
for discriminating probable DLB and specificity of 90.4% 
for excluding non-DLB dementia. Based on these find-
ings, low DAT uptake was given the diagnostic import-
ance as a suggestive feature of DLB.   
Despite these clinical studies, the usefulness of DAT 
imaging for the diagnosis of DLB remains controversial.
80 
Further studies are awaited. 
 
123I-Metaiodobenzylguanidine 
MIBG is a physiological analogue of norepinephrine 
and competes with it for neuronal uptake at the sympa-
thetic nerve terminal.
81-83 MIBG myocardial scintigraphy 
was originally used to assess myocardial sympathetic 
nerve damage in heart disease.
84-86 Later this method was 
applied to detect cardiac sympathetic denervation in PD 
and clinically used to discriminate PD from other neuro-
logical disorders with extrapyramidal signs (EPS).
87-89 
The heart-to-mediastinum ratio of myocardial MIBG up-
take and the washout rate in percent are used to assess the 
severity of the postganglionic cardiac sympathetic nerve 
denervation. Recent studies have demonstrated that MIBG 
myocardial scintigraphy is useful for the clinical diag-
nosis of DLB.
90-93 The latest guidelines include abnormal 
MIBG myocardial scintigraphy as one of the supportive 
features which commonly present in DLB but are not 
proven to have diagnostic specificity. 
Yoshita et al.
90 first reported the clinical usefulness of 
MIBG scintigraphy to distinguish DLB from other de-
mentias by investigating 14 subjects with DLB. The cli-
nical difficulty of discriminating DLB from AD stems 
from the fact that there are many AD cases with EPS 
and DLB cases without Parkinsonism. MIBG myocar-
dial scintigraphy detected disturbances of cardiac sym-
pathetic nerves in patients with DLB regardless of cli-
nically-evident Parkinsonism, whereas AD patients with 
EPS showed no significant decrease of MIBG uptake.
94,95 
Yoshita’s group performed MIBG myocardial scinti-
graphy on 37 probable DLB patients including 7 cases 
without EPS, 42 probable AD subjects and 10 normal 
controls.
95 They reported that setting the cut-off value of 
the heart-to-mediastinum ratio at 1.68 yielded 100% sen-
sitivity and specificity for differentiating DLB from AD. 
Similarly, setting the washout-rate cut-off value at 23.6% 
yielded 87% sensitivity and 83% specificity.  
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In comparing the clinical value of brain-perfusion SP-
ECT and MIBG myocardial scintigraphy, Hanyu et al.
96 
observed decreased heart-to-mediastinum ratios in all 19 
DLB patients, while only 14 of them showed occipital 
hypoperfusion. They concluded that MIBG myocardial 
scintigraphy could improve sensitivity in the detection of 
DLB. The results of our study were consistent with those 
from Hanyu’s study. Twenty-four of 25 subjects (96%) 
had decreased cardiac MIBG uptake in the delayed im-
age (3 hours after injection), while occipital hypoper-
fusion was observed in only 68% and 76% of them by 
applying, respectively, eZIS and 3DSRT.
68 Most studies 
on MIBG myocardial scintigraphy thus far have been 
conducted by Japanese groups. However, a Spanish team 
recently reported that a heart-to-mediastinum-ratio cut-
off value of 1.36 differentiated DLB from other demen-
tias with a sensitivity of 94% and a specificity of 96%.
97 
At the 4th International Workshop on DLB and PDD, 
there was a heated debate about whether abnormal MI-
BG myocardial scintigraphy should be included as a sug-
gestive feature for DLB. At present, there is not enough 
evidence to thoroughly validate the usefulness of MIBG 
myocardial scintigraphy in the diagnosis of DLB, and we 
still need to accumulate more data. 
 
Conclusion 
 
DLB has been reported to be the second most common 
type of degenerative dementia. However, DLB is often 
under-diagnosed and its discrimination from other demen-
tias is very difficult, especially at its early stages. Since 
DLB has specific impairments and functional disabili-
ties, its early and accurate diagnosis is very important 
for a better prognosis. To achieve such an improved prog-
nosis, neuroimaging studies and MIBG myocardial scin-
tigraphy play important roles. Further research is needed 
to establish their clinical usefulness even further. 
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